Evoke Pharma Inc. (NASDAQ:EVOK) was up 3.7% during mid-day trading on Thursday . The stock traded as high as $2.27 and last traded at $2.24, with a volume of 297,268 shares traded. The stock had previously closed at $2.16.

Several equities research analysts have issued reports on EVOK shares. FBR & Co boosted their price objective on shares of Evoke Pharma to $9.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 19th. Rodman & Renshaw downgraded shares of Evoke Pharma from a “buy” rating to a “neutral” rating and set a $2.00 price objective for the company. in a research note on Monday, July 18th. Brean Capital downgraded shares of Evoke Pharma from a “buy” rating to a “hold” rating in a research note on Monday, July 18th. Feltl & Co. downgraded shares of Evoke Pharma from a “strong-buy” rating to a “sell” rating in a research note on Monday, July 18th. Finally, Northland Securities downgraded shares of Evoke Pharma from an “outperform” rating to a “market perform” rating in a research note on Monday, July 18th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and three have given a buy rating to the company. The company has an average rating of “Hold” and an average target price of $13.34.

The stock’s market capitalization is $16.94 million. The firm’s 50-day moving average is $4.77 and its 200 day moving average is $4.68.

Evoke Pharma (NASDAQ:EVOK) last posted its quarterly earnings results on Wednesday, May 11th. The specialty pharmaceutical company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.41) by $0.04. Analysts anticipate that Evoke Pharma Inc. will post ($1.43) EPS for the current fiscal year.

In other news, major shareholder Parters Vii L. P. Domain sold 344,120 shares of the stock in a transaction that occurred on Thursday, May 26th. The shares were sold at an average price of $4.70, for a total value of $1,617,364.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.